Antihypertensive ‘Edarbi’ acquires approval from MFDS

Published: 2017-06-01 10:17:12

Updated: 2017-06-01 10:17:12

Takeda Pharmaceuticals Korea(CEO Mahender Nayak, hereinafter referring to Takeda) announced ‘Edarbi(potassium azilsartan medoxomil),’ an essential hypertensive treatment, acquired commercialization approval from the Ministry of Food and Drug Safety on the 29^th.

‘Edarbi,’ an angiotensin II receptor blocker(ARB) antihypertensive, reduces blood pressure by blocking angiotensin II receptors to inh...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.